Delving into the Latest Updates on Institute For Pharmaceutical Research with Synapse

Overview

Polycystic Ovarian Syndrome (PCOS) is a disorder of endocrine system characterized by irregular menstrual cycles, high androgen levels, and polycystic ovaries. The aim of this study is to evaluate pharmacological activity of Rubia cordifolia (RC) in treating letrozole-induced PCOS in rats that exhibit metabolic and endocrinal criteria of PCOS patients. The plant RC was collected, characterized and prepared an extract, to obtained the phenolic and flavonoid content, which was confirmed by GC-MS. Obtained and confirmed content are proceeded for molecular docking and in-vivo study. The results of molecular docking found the favourable receptorligand interactions. and exhibited strong binding affinities (below -5 kcal/mol), The top-priority target genes were found to BRAC1, and PKD1. Further, in-vivo study was performed in female Wistar rats and PCOS was induced by oral administration of letrozole (1 mg/kg, per orally, p.o., 21-days). Due to PCOS significantly increases body-weight, ovarian weight/size, and cysts, while reduction in FSH level and fluctuation in glucose and LH levels. Then, rats were treated with different dose of RC extract (100/200/400 mg/kg/day, p.o.), and metformin take as standard (20 mg/kg/day, p.o.). Resulted in a significantly decrease body-weight, ovarian weight/size, maintain glucose and hormones level. Additionally, histological analysis of rat ovaries revealed a fewer cyst in treated group compared to the untreated group. All of these effects were significantly reduced by RC administration. Our results proved that RC ameliorates letrozole-induced PCOS.

07 Apr 2025·Molecular Pharmaceutics

Crafting a Molecular Trojan Horse: Sialic Acid-Modified PLGA Nanoparticles for Targeted Lung Cancer Therapy

Article

Author: Jatin ; Kumar, Krishan ; Tiwari, Siddharth ; Saini, Manjit ; Mishra, Mohini ; Priya ; Mishra, Brahmeshwar ; Chawla, Ruchi ; Rani, Varsha

The glycan receptors prominently expressed on the surface of lung cancer cells offers promising targets for drug delivery. The prepared gemcitabine (GB)-loaded PLGA-NPs and sialic acid (Siac)-modified PLGA-NPs exhibited a uniform polydispersity index (PDI) value below 0.3, a particle size under 200 nm, and negative zeta potentials ranging from -17.45 to -21.45 mV. Entrapment efficiency (% EE) and drug loading values exceeded 70% and 8%, respectively. SEM and TEM showed that the particles were uniformly dispersed with a spherical shape. FTIR, XRD, TGA, and DSC analyses indicated the physiochemical stability of the drug within the nanoformulations. Controlled (26.92 to 31.64% within 24 h at pH 7.4) and pH-sensitive (36.80 to 40.25% within 24 h at pH 5.5) GB release were observed for the different formulations of PLGA-NPs. The MTT cytotoxicity assay revealed IC50 values for the GB control, GB-PLGA-NPs, and GB-PLGA-Siac-NPs as 13.65 ± 1.20, 8.14 ± 1.24, and 4.16 ± 1.05 μg/mL, respectively. The Co6-GB-PLGA-Siac-NPs showed significantly higher cellular uptake than that of the Co6-GB control (p < 0.001) and Co6-GB-PLGA-NPs (p < 0.01) respectively. Pharmacokinetic profiles indicated higher AUC values (ng·h/mL) for GB-PLGA-Siac-NPs (8355.07 ± 2006.45) compared to GB-PLGA-NPs (6145.58 ± 969.25) and the GB control (1510.72 ± 81.08), resulting in higher bioavailability of GB-PLGA-Siac-NPs. Biodistribution studies confirmed superior localization of DiD-GB-PLGA-Siac-NPs, indicated by radiant efficiency signal on B[a]P induced lung cancerous tissues relative to DiD-GB-PLGA-NPs after 1 h (p < 0.001), 4 h (p < 0.01), and 12 h (p < 0.001), which could be attributed to their ability to target glycans. In vivo anticancer efficacy in a B[a]P-induced lung cancer mice model depicted that GB-PLGA-Siac-NPs effectively inhibited lung cancer cells and reduced systemic toxicity, as evidenced by the average number of lung cancer cells, body weight values, survival analysis, biochemical parameters associated with organs (such as the liver and kidney), and histopathological analysis. Therefore, GB-loaded Siac-coated PLGA nanoparticles could serve as an efficient vehicle for GB delivery via targeting glycan receptors in lung cancer therapy.

18 Mar 2025·Current Pharmaceutical Design

Identification of Natural Compounds as Potential COVID-19 Main Protease (Mpro) Inhibitors: A Comprehensive Study and In silico Evidence

Article

Author: Khan, Zaved Ahmed ; Devi, Arti ; Kaur, Gursharan ; Dewangan, Hitesh Kumar ; Shiven, Aditya ; Shah, Kamal ; Dwibedi, Vagish ; Jain, Sahil ; Mandal, Sudip Kumar ; Rath, Santosh Kumar

SARS-CoV-2, the virus responsible for COVID-19, has resulted in a devastating global impact with millions of lives lost. Remdesivir and 2-DG are among the few drugs authorized for emergency use against COVID-19, but concerns about their efficacy and side effects persist. Vaccines have been developed and approved, yet the emergence of viral mutations has raised questions about their effectiveness against new variants. Natural compounds with antiviral properties have shown promise in combating SARS-CoV-2. The review highlights the potential of medicinal plant compounds, particularly in targeting the virus' main protease, a crucial component for viral replication. Natural, plant-derived compounds represent a promising avenue for COVID-19 therapeutics. Further clinical validation is necessary to ascertain their efficacy and safety in treating COVID-19. This underscores the importance of continued research into alternative treatments for combating this global health crisis. This review examines the potential of natural, plant-derived compounds as safe and cost-effective alternatives for combating COVID-19. It summarizes the pathogenesis of SARS-CoV- 2 and the ongoing drug studies and identifies natural compounds with known antiviral properties. Additionally, it explores the potential of medicinal plant compounds in targeting the SARS-CoV-2 main protease through in silico and molecular docking studies.

100 Deals associated with Institute For Pharmaceutical Research

Login to view more data

100 Translational Medicine associated with Institute For Pharmaceutical Research

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

6

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

IPR-6001	Pain More	Discontinued
IPR-6010	Wounds and Injuries More	Pending
Growth factor complex(Institute For Pharmaceutical Research)	Skin Diseases More	Pending
IPR-2000	Obesity More	Pending
IPR-3100	Thrombosis More	Pending